Research Article Details
| Article ID: | A26620 |
| PMID: | 20082871 |
| Source: | Arch Med Res |
| Title: | High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. |
| Abstract: | BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) is closely associated with insulin resistance and metabolic syndrome. Prevalence of NAFLD increases greatly in patients with type 2 diabetes mellitus (T2DM), and it may also increase cardiovascular disease mortality and morbidity. The aim of our study was to investigate the prevalence of NAFLD in T2DM population and to compare the prevalence of coronary heart disease (CHD) and its risk factors between diabetic patients with and without NAFLD in a Chinese population. METHODS: A cross-sectional survey was conducted among 560 cases of in-patient T2DM patients from January 2002 to January 2009 in southern China. Patients were divided into two groups (NAFLD and non-NAFLD) and underwent clinical examination, anthropometry, laboratory tests and routine liver ultrasonography. RESULTS: Prevalence of NAFLD was 75.18% (421 cases) among all participants, and 285 cases (67.70%) had normal liver function and no symptoms. NAFLD group had higher body mass index (BMI), waist/hip circumference ratio (WHR), alanine aminotransferase (ALT), triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) levels than those without NAFLD (p<0.01). Moreover, the prevalence of CHD was also higher in the NAFLD group (p<0.01), especially in those male patients with elevated plasma ALT. CONCLUSIONS: NAFLD is a common condition among T2DM patients. Its occurrence may be related to sex, age, abdominal obesity, dyslipidemia metabolism, etc. and it is associated with a higher prevalence of CHD. Plasma ALT levels may act as a marker. |
| DOI: | 10.1016/j.arcmed.2009.07.009 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |